Aptargroup

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Aptargroup and other ETFs, options, and stocks.

About ATR

AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions, and services for the prescription drug, consumer health care, injectable, active packaging, beauty, personal care, home care, and food and beverages industries. It operates through the following segments: Pharma, Beauty and Home, and Food and Beverage. 

CEO
Stephan B. Tanda
CEOStephan B. Tanda
Employees
13,500
Employees13,500
Headquarters
Crystal Lake, Illinois
HeadquartersCrystal Lake, Illinois
Founded
1940
Founded1940
Employees
13,500
Employees13,500

ATR Key Statistics

Market cap
8.10B
Market cap8.10B
Price-Earnings ratio
19.67
Price-Earnings ratio19.67
Dividend yield
1.49%
Dividend yield1.49%
Average volume
617.84K
Average volume617.84K
High today
$123.03
High today$123.03
Low today
$121.32
Low today$121.32
Open price
$123.03
Open price$123.03
Volume
304.88K
Volume304.88K
52 Week high
$164.28
52 Week high$164.28
52 Week low
$103.23
52 Week low$103.23

Stock Snapshot

With a market cap of 8.1B, Aptargroup(ATR) trades at $122.19. The stock has a price-to-earnings ratio of 19.67 and currently yields dividends of 1.5%.

During the trading session on 2025-12-24, Aptargroup(ATR) shares reached a daily high of $123.03 and a low of $121.32. At a current price of $122.19, the stock is +0.7% higher than the low and still -0.7% under the high.

Trading volume for Aptargroup(ATR) stock has reached 304.88K, versus its average volume of 617.84K.

Over the past 52 weeks, Aptargroup(ATR) stock has traded between a high of $164.28 and a low of $103.23.

Over the past 52 weeks, Aptargroup(ATR) stock has traded between a high of $164.28 and a low of $103.23.

ATR News

Simply Wall St 5d
How Investors Are Reacting To AptarGroup Landing Its First Dual Bidose Cardiovascular Nasal Product

AptarGroup recently announced that its Bidose Liquid Nasal Spray System is the delivery mechanism for Milestone Pharmaceuticals’ newly FDA-approved CARDAMYST (e...

How Investors Are Reacting To AptarGroup Landing Its First Dual Bidose Cardiovascular Nasal Product
Simply Wall St 6d
AptarGroup: Assessing Valuation After CARDAMYST Nasal Spray Milestone in Drug Delivery Solutions

AptarGroup (ATR) just notched an important milestone, as its Bidose nasal spray system is the delivery platform for newly FDA approved CARDAMYST, a PSVT treatme...

AptarGroup: Assessing Valuation After CARDAMYST Nasal Spray Milestone in Drug Delivery Solutions

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

People also own

Based on the portfolios of people who own ATR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.